Therapeutic implications of germline testing in patients with advanced cancers

Analysis of 11,947 patients with over 50 malignancies found that 8% of advanced cancer harbored a germline variant with therapeutic actionability, with 40% of these patients receiving germline genotype-directed treatment. The authors conclude that germline sequence analysis is additive to tumor sequence analysis for therapy selection and should be considered for all patients with advanced cancer.